You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameParamethasone
Accession NumberDB01384
TypeSmall Molecule
GroupsApproved
DescriptionA glucocorticoid with the general properties of corticosteroids. It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone. (From Martindale, The Extra Pharmacopoeia, 30th ed, p737)
Structure
Thumb
Synonyms
Dillar
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HaldroneNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Paramethasone acetate
ThumbNot applicableDBSALT001420
Categories
UNIIVFC6ZX3584
CAS number53-33-8
WeightAverage: 392.4611
Monoisotopic: 392.199902243
Chemical FormulaC22H29FO5
InChI KeyInChIKey=MKPDWECBUAZOHP-AFYJWTTESA-N
InChI
InChI=1S/C22H29FO5/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-20(15,2)19(13)17(26)9-21(14,3)22(11,28)18(27)10-24/h4-5,7,11,13-14,16-17,19,24,26,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20+,21+,22+/m1/s1
IUPAC Name
(1S,2R,8S,10S,11S,13R,14R,15S,17S)-8-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1([H])[C@@]2([H])C[C@]([H])(F)C2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 6-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone.
PharmacodynamicsParamethasone is a glucocorticoid with the general properties of corticosteroids. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.
Mechanism of actionGlucocorticoids such as paramethasone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Paramethasone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding80%
Metabolism

Hepatic.

Route of eliminationCorticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Half lifeNot Available
ClearanceNot Available
ToxicitySide effects include inhibition of bone formation, suppression of calcium absorption delayed wound healing, immune suppression, and hyperglycemia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9948
Blood Brain Barrier+0.971
Caco-2 permeable+0.747
P-glycoprotein substrateSubstrate0.7725
P-glycoprotein inhibitor INon-inhibitor0.7629
P-glycoprotein inhibitor IINon-inhibitor0.9002
Renal organic cation transporterNon-inhibitor0.8405
CYP450 2C9 substrateNon-substrate0.8789
CYP450 2D6 substrateNon-substrate0.9031
CYP450 3A4 substrateSubstrate0.6991
CYP450 1A2 substrateNon-inhibitor0.9313
CYP450 2C9 inhibitorNon-inhibitor0.9254
CYP450 2D6 inhibitorNon-inhibitor0.939
CYP450 2C19 inhibitorNon-inhibitor0.9234
CYP450 3A4 inhibitorNon-inhibitor0.7563
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8979
Ames testNon AMES toxic0.8509
CarcinogenicityNon-carcinogens0.9232
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3293 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9794
hERG inhibition (predictor II)Non-inhibitor0.6022
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.145 mg/mLALOGPS
logP1.51ALOGPS
logP1.3ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)12.45ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.79 m3·mol-1ChemAxon
Polarizability40.84 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesH02AB05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Paramethasone is combined with 1,10-Phenanthroline.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Paramethasone.
AldesleukinParamethasone may decrease the antineoplastic activities of Aldesleukin.
Aluminum hydroxideThe bioavailability of Paramethasone can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Paramethasone can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Paramethasone is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Paramethasone.
AmiodaroneThe serum concentration of Paramethasone can be increased when it is combined with Amiodarone.
Amphotericin BParamethasone may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Paramethasone can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Paramethasone can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Paramethasone can be decreased when combined with Atomoxetine.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Paramethasone.
BazedoxifeneThe serum concentration of Paramethasone can be increased when it is combined with Bazedoxifene.
BendroflumethiazideParamethasone may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Paramethasone.
BexaroteneThe serum concentration of Paramethasone can be decreased when it is combined with Bexarotene.
Bismuth SubcitrateThe bioavailability of Paramethasone can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Paramethasone can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Paramethasone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Paramethasone can be decreased when it is combined with Bosentan.
BumetanideParamethasone may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Paramethasone.
Calcium carbonateThe bioavailability of Paramethasone can be decreased when combined with Calcium carbonate.
CarbamazepineThe serum concentration of Paramethasone can be decreased when it is combined with Carbamazepine.
CeritinibThe serum concentration of Paramethasone can be increased when it is combined with Ceritinib.
CeritinibParamethasone may increase the hyperglycemic activities of Ceritinib.
ChlorothiazideParamethasone may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Paramethasone can be increased when it is combined with Chlorotrianisene.
ChlorthalidoneParamethasone may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Paramethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClarithromycinThe serum concentration of Paramethasone can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Paramethasone can be decreased when combined with Clemastine.
ClotrimazoleThe metabolism of Paramethasone can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Paramethasone can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Paramethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Paramethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Paramethasone can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Paramethasone can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Paramethasone.
CoumaphosThe risk or severity of adverse effects can be increased when Paramethasone is combined with Coumaphos.
CrizotinibThe metabolism of Paramethasone can be decreased when combined with Crizotinib.
CyclosporineThe metabolism of Paramethasone can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Paramethasone can be decreased when it is combined with Dabrafenib.
DarunavirThe serum concentration of Paramethasone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Paramethasone can be increased when it is combined with Dasatinib.
DecamethoniumThe risk or severity of adverse effects can be increased when Paramethasone is combined with Decamethonium.
DeferasiroxThe serum concentration of Paramethasone can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Paramethasone is combined with Deferasirox.
DelavirdineThe metabolism of Paramethasone can be decreased when combined with Delavirdine.
DemecariumThe risk or severity of adverse effects can be increased when Paramethasone is combined with Demecarium.
DexamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Dexamethasone.
DichlorvosThe risk or severity of adverse effects can be increased when Paramethasone is combined with Dichlorvos.
DienestrolThe serum concentration of Paramethasone can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Paramethasone can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Paramethasone.
DihydroergotamineThe metabolism of Paramethasone can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneParamethasone may increase the fluid retaining activities of Dihydrotestosterone.
DiltiazemThe metabolism of Paramethasone can be decreased when combined with Diltiazem.
DonepezilThe risk or severity of adverse effects can be increased when Paramethasone is combined with Donepezil.
DoxycyclineThe metabolism of Paramethasone can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Paramethasone can be decreased when combined with Dronedarone.
EchothiophateThe risk or severity of adverse effects can be increased when Paramethasone is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Paramethasone is combined with Edrophonium.
EfavirenzThe serum concentration of Paramethasone can be decreased when it is combined with Efavirenz.
EnzalutamideThe serum concentration of Paramethasone can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Paramethasone can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Paramethasone can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Paramethasone can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Paramethasone can be increased when it is combined with Estriol.
EstroneThe serum concentration of Paramethasone can be increased when it is combined with Estrone.
Etacrynic acidParamethasone may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Paramethasone can be increased when it is combined with Ethinyl Estradiol.
EtravirineThe serum concentration of Paramethasone can be decreased when it is combined with Etravirine.
FenthionThe risk or severity of adverse effects can be increased when Paramethasone is combined with Fenthion.
FluconazoleThe metabolism of Paramethasone can be decreased when combined with Fluconazole.
FluoxymesteroneParamethasone may increase the fluid retaining activities of Fluoxymesterone.
FluvoxamineThe metabolism of Paramethasone can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Paramethasone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Paramethasone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Paramethasone can be decreased when it is combined with Fosphenytoin.
FurosemideParamethasone may increase the hypokalemic activities of Furosemide.
Fusidic AcidThe serum concentration of Paramethasone can be increased when it is combined with Fusidic Acid.
GalantamineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Paramethasone is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of Paramethasone can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Paramethasone is combined with Ginkgo biloba.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Paramethasone.
HexestrolThe serum concentration of Paramethasone can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Paramethasone is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Paramethasone.
HydrochlorothiazideParamethasone may increase the hypokalemic activities of Hydrochlorothiazide.
HydroflumethiazideParamethasone may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Paramethasone can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Paramethasone can be decreased when combined with Imatinib.
IndacaterolIndacaterol may increase the hypokalemic activities of Paramethasone.
IndapamideParamethasone may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Paramethasone can be increased when it is combined with Indinavir.
IsavuconazoniumThe metabolism of Paramethasone can be decreased when combined with Isavuconazonium.
IsoflurophateThe risk or severity of adverse effects can be increased when Paramethasone is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Paramethasone.
IsradipineThe metabolism of Paramethasone can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Paramethasone can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Paramethasone can be increased when it is combined with Ivacaftor.
KetoconazoleThe serum concentration of Paramethasone can be increased when it is combined with Ketoconazole.
LopinavirThe serum concentration of Paramethasone can be increased when it is combined with Lopinavir.
LovastatinThe metabolism of Paramethasone can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Paramethasone can be increased when it is combined with Luliconazole.
MagaldrateThe bioavailability of Paramethasone can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Paramethasone can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Paramethasone can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Paramethasone can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Paramethasone can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Paramethasone is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Paramethasone.
MestranolThe serum concentration of Paramethasone can be increased when it is combined with Mestranol.
MethyclothiazideParamethasone may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneParamethasone may increase the fluid retaining activities of Methyltestosterone.
MetolazoneParamethasone may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of Paramethasone can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Minaprine.
MitotaneThe serum concentration of Paramethasone can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Paramethasone.
ModafinilThe serum concentration of Paramethasone can be decreased when it is combined with Modafinil.
NafcillinThe serum concentration of Paramethasone can be decreased when it is combined with Nafcillin.
NefazodoneThe serum concentration of Paramethasone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Paramethasone can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Neostigmine.
NetupitantThe serum concentration of Paramethasone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Paramethasone can be decreased when combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Paramethasone is combined with Nicorandil.
NilotinibThe metabolism of Paramethasone can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Paramethasone.
OlaparibThe metabolism of Paramethasone can be decreased when combined with Olaparib.
OsimertinibThe serum concentration of Paramethasone can be increased when it is combined with Osimertinib.
OxandroloneParamethasone may increase the fluid retaining activities of Oxandrolone.
OxymetholoneParamethasone may increase the fluid retaining activities of Oxymetholone.
PalbociclibThe serum concentration of Paramethasone can be increased when it is combined with Palbociclib.
PentobarbitalThe serum concentration of Paramethasone can be decreased when it is combined with Pentobarbital.
PhenobarbitalThe serum concentration of Paramethasone can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Paramethasone.
PhenytoinThe serum concentration of Paramethasone can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Physostigmine.
PiretanideParamethasone may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of Paramethasone can be increased when it is combined with Polyestradiol phosphate.
PolythiazideParamethasone may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of Paramethasone can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Paramethasone can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Pyridostigmine.
QuinestrolThe serum concentration of Paramethasone can be increased when it is combined with Quinestrol.
QuinethazoneParamethasone may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Rabies vaccine.
RanolazineThe metabolism of Paramethasone can be decreased when combined with Ranolazine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Paramethasone.
RifabutinThe serum concentration of Paramethasone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Paramethasone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Paramethasone can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Paramethasone can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Rivastigmine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Paramethasone.
SaquinavirThe serum concentration of Paramethasone can be increased when it is combined with Saquinavir.
SildenafilThe metabolism of Paramethasone can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Paramethasone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Paramethasone can be increased when it is combined with Simeprevir.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Paramethasone.
St. John's WortThe serum concentration of Paramethasone can be decreased when it is combined with St. John's Wort.
StanozololParamethasone may increase the fluid retaining activities of Stanozolol.
StiripentolThe serum concentration of Paramethasone can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Paramethasone can be decreased when combined with Sulfisoxazole.
Synthetic Conjugated Estrogens, AThe serum concentration of Paramethasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Paramethasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Tacrine.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Paramethasone.
TelaprevirThe serum concentration of Paramethasone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Paramethasone can be increased when it is combined with Telithromycin.
TestosteroneParamethasone may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of Paramethasone can be increased when it is combined with Tibolone.
TiclopidineThe metabolism of Paramethasone can be decreased when combined with Ticlopidine.
TocilizumabThe serum concentration of Paramethasone can be decreased when it is combined with Tocilizumab.
TorasemideParamethasone may increase the hypokalemic activities of Torasemide.
TrichlorfonThe risk or severity of adverse effects can be increased when Paramethasone is combined with Trichlorfon.
TrichlormethiazideParamethasone may increase the hypokalemic activities of Trichlormethiazide.
TubocurarineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Tubocurarine.
VenlafaxineThe metabolism of Paramethasone can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Paramethasone can be decreased when combined with Verapamil.
VoriconazoleThe serum concentration of Paramethasone can be increased when it is combined with Voriconazole.
WarfarinParamethasone may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Paramethasone can be increased when it is combined with Zeranol.
ZiprasidoneThe metabolism of Paramethasone can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG: Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med. 2006 Jan;36(1):37-43. Epub 2005 Oct 28. [PubMed:16255837 ]
  2. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588 ]
  3. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [PubMed:16895953 ]
  4. Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [PubMed:16980198 ]
  5. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445 ]
  6. Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [PubMed:17086345 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on July 06, 2007 14:34 / Updated on August 17, 2016 12:23